SG11201510330YA - Methods for promoting neuronal development and/or health comprising administration of a combination of docosahexaenoic acid and alpha-lipoic acid - Google Patents

Methods for promoting neuronal development and/or health comprising administration of a combination of docosahexaenoic acid and alpha-lipoic acid

Info

Publication number
SG11201510330YA
SG11201510330YA SG11201510330YA SG11201510330YA SG11201510330YA SG 11201510330Y A SG11201510330Y A SG 11201510330YA SG 11201510330Y A SG11201510330Y A SG 11201510330YA SG 11201510330Y A SG11201510330Y A SG 11201510330YA SG 11201510330Y A SG11201510330Y A SG 11201510330YA
Authority
SG
Singapore
Prior art keywords
alpha
administration
health
methods
combination
Prior art date
Application number
SG11201510330YA
Other languages
English (en)
Inventor
Chenzhong Kuang
Yan Xiao
Eduard K Poels
Zeina Jouni
Dirk Hondmann
Original Assignee
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mjn Us Holdings Llc filed Critical Mjn Us Holdings Llc
Publication of SG11201510330YA publication Critical patent/SG11201510330YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Pediatric Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201510330YA 2013-07-16 2014-06-21 Methods for promoting neuronal development and/or health comprising administration of a combination of docosahexaenoic acid and alpha-lipoic acid SG11201510330YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/942,827 US9226914B2 (en) 2013-07-16 2013-07-16 Methods for promoting neuronal development and/or health
PCT/US2014/043532 WO2015009407A1 (fr) 2013-07-16 2014-06-21 Procédé pour stimuler le développement et/ou la santé neuronal(e) comprenant l'administration d'une combinaison d'acide docosahexaénoïque et d'acide alpha-lipoïque

Publications (1)

Publication Number Publication Date
SG11201510330YA true SG11201510330YA (en) 2016-01-28

Family

ID=51210794

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201510330YA SG11201510330YA (en) 2013-07-16 2014-06-21 Methods for promoting neuronal development and/or health comprising administration of a combination of docosahexaenoic acid and alpha-lipoic acid

Country Status (13)

Country Link
US (1) US9226914B2 (fr)
EP (1) EP3102196A1 (fr)
CN (1) CN105358144B (fr)
AR (1) AR096942A1 (fr)
AU (1) AU2014290767A1 (fr)
BR (1) BR112015031416A2 (fr)
CA (1) CA2918460A1 (fr)
HK (1) HK1221658A1 (fr)
MX (1) MX2016000423A (fr)
PH (1) PH12016500025A1 (fr)
SG (1) SG11201510330YA (fr)
TW (1) TW201542101A (fr)
WO (1) WO2015009407A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150290261A1 (en) * 2014-04-10 2015-10-15 Mead Johnson Nutrition Company Methods of use for probiotics and prebiotics
US10525016B2 (en) * 2015-06-03 2020-01-07 Mead Johnson Nutrition Company Nutritional compositions containing an elevated level of inositol and uses thereof
US10617701B2 (en) * 2015-07-10 2020-04-14 Mead Johnson Nutrition Company Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
CN110891982B (zh) 2017-04-17 2023-12-22 芝加哥大学 向肠道递送短链脂肪酸以用于人体保健和疾病治疗的聚合物材料
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61701B1 (en) 1986-07-17 1994-11-30 Morinaga Milk Industry Co Ltd Process for producing bovine lactoferrin in high purity
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
DK165090D0 (da) 1990-07-09 1990-07-09 Kem En Tec As Konglomererede partikler
WO1992012711A1 (fr) 1991-01-24 1992-08-06 Martek Corporation Melanges d'huiles microbiennes et utilisations de ces melanges
US5374567A (en) 1993-05-20 1994-12-20 The United States Of America As Represented By The Secretary Of The Navy Operational amplifier using bipolar junction transistors in silicon-on-sapphire
EP0744901B1 (fr) 1994-02-16 2001-12-05 Pharming Intellectual Property BV Isolation de la lactoferrine du lait
SE9503926D0 (sv) 1995-11-07 1995-11-07 Pharmacia Biotech Ab Adsorptionsförfarande och separationsmedium
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
EP1087828B1 (fr) 1998-06-18 2008-09-17 Upfront Chromatography A/S Sous-systeme d'adsorption a lit expanse
AU5823801A (en) 2000-05-12 2001-11-20 Upfront Chromatography As A bed adsorption system
US6332533B1 (en) 2000-08-29 2001-12-25 H.H.H. Incorprorated Media holder mouse pad
EP2272378B1 (fr) 2001-06-01 2014-08-06 Upfront Chromatography A/S Fractionnement de mélanges contenant des protéines
AU2003218623B2 (en) 2002-03-07 2008-01-17 Upfront Chromatography A/S A process of isolating lactoferrin
US20050107338A1 (en) 2003-11-17 2005-05-19 Seidman Michael D. Nutritional supplement enhancing mitochondrial function
CN103734746B (zh) * 2004-07-19 2017-01-11 纽崔西亚公司 天冬氨酸用于调节血中葡萄糖水平的用途
US8883814B2 (en) 2006-06-05 2014-11-11 Keyview Labs, Inc. Compositions and methods for enhancing brain function
US20080003330A1 (en) 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
EP2251030A1 (fr) 2009-05-12 2010-11-17 Nestec S.A. Lactoferrine et santé mentale et développement chez les enfants
EP2258218A1 (fr) 2009-06-02 2010-12-08 Nestec S.A. Composition nutritionnelle pour supporter le développement cérébral et fonction des tout-petits
US20120219526A1 (en) 2009-10-29 2012-08-30 Nestec S.A. Nutritional compositions comprising lactoferrin and probiotics and kits of parts thereof
WO2011069987A1 (fr) * 2009-12-08 2011-06-16 Nestec S.A. Lait maternisé comprenant des probiotiques et des composants de membrane de globule gras du lait
EP2554058A4 (fr) * 2010-03-31 2013-12-25 Vegenat S A Complément alimentaire fonctionnel spécialement destiné à la nutrition, à la prévention et à l'atténuation d'altérations neurologiques ou neurodégénératives ou de troubles cognitifs
US8968722B2 (en) * 2010-12-29 2015-03-03 Mead Johnson Nutrition Company Milk-based nutritional compositions containing lactoferrin and uses thereof
CN102318827B (zh) 2011-07-15 2013-02-27 浙江康恩贝健康产品有限公司 一种促进神经系统发育的营养素组合物及保健品
EP2609814A1 (fr) 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 pour le développement de la fonction cognitive
US20140179775A1 (en) 2012-02-29 2014-06-26 Mead Johnson Nutrition Company Neurogenesis screening method and uses thereof
US20140199265A1 (en) 2013-01-11 2014-07-17 Mead Johnson Nutrition Company Nutritional compositions containing a neurologic component and uses thereof

Also Published As

Publication number Publication date
US9226914B2 (en) 2016-01-05
CA2918460A1 (fr) 2015-01-22
AU2014290767A1 (en) 2015-12-24
EP3102196A1 (fr) 2016-12-14
PH12016500025A1 (en) 2016-03-28
AR096942A1 (es) 2016-02-10
WO2015009407A1 (fr) 2015-01-22
BR112015031416A2 (pt) 2017-07-25
CN105358144B (zh) 2018-05-11
CN105358144A (zh) 2016-02-24
US20150023923A1 (en) 2015-01-22
MX2016000423A (es) 2016-04-20
HK1221658A1 (zh) 2017-06-09
TW201542101A (zh) 2015-11-16

Similar Documents

Publication Publication Date Title
IL273688A (en) Evaluation and treatment of bradykinin-mediated disorders
HK1222552A1 (zh) 索布替羅用於治療髓鞘形成疾病
EP2890440A4 (fr) Dispositifs et procédés pour le traitement d'une maladie vasculaire
HK1207574A1 (en) Treatment of myelosuppression
SG11201602181UA (en) Catheter for plaque stablisation
PL3004108T3 (pl) Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób
HK1222771A1 (zh) 促進神經元發育和/或健康的方法
HK1221658A1 (zh) 包括給予二十二碳六烯酸和α-硫辛酸的組合的用於促進神經元發育和/或健康的方法
EP2941252A4 (fr) Utilisation de conjugués d'acides gras et de niacine en vue du traitement de maladies
SG10201708758UA (en) Method of presenting health care information
ZA201508452B (en) Oral formulation for the treatment of cardiovascular diseases
HK1210683A1 (en) Apparatus for treatment of cavities in a human body
EP2825614A4 (fr) Fluides de traitement comprenant un acide hydroxypyridinecarboxylique et leurs procédés d'utilisation
HK1203955A1 (zh) 反式- -癸烯酸衍生物及含有其的藥物
EP2922392A4 (fr) Modèle animal de lésion neuronale
IL245100A0 (en) Methods for treating stomatitis associated with m-tor inhibitors
IL235270B (en) A device for treating sinuses in the human body
IL227344A0 (en) A method for increasing drug effectiveness and reducing side effects